

## **BD launches POC SARS-CoV-2 antigen test**

written by CAP TODAY  
August 19, 2020

August 2020—Becton Dickinson announced that the FDA granted emergency use authorization to the BD Veritor Plus System for Rapid Detection of SARS-CoV-2 Assay, a point-of-care diagnostic test for use with the BD Veritor Plus System.



©2026 CAP TODAY, all rights reserved.

---

## **Flagship launches clinical diagnostics service**

written by CAP TODAY  
August 19, 2020

August 2020—Flagship Biosciences launched a clinical diagnostics immuno-oncology service, TissueInsight, which provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment, including information on tumor infiltrating lymphocytes and macrophages.



©2026 CAP TODAY, all rights reserved.

---

## **Qiagen web series on biomarker profiling from**

## [FFPE samples](#)

written by CAP TODAY  
August 19, 2020

Aug. 18, 2020—Qiagen is offering a four-part web seminar series in which the latest tips and tricks for successful biomarker profiling from FFPE samples will be discussed.



©2026 CAP TODAY, all rights reserved.

---

## [LigoLab LIS and RCM operating platform](#)

written by CAP TODAY  
August 19, 2020

Aug. 17, 2020—LigoLab Information Systems offers a collection model that combines laboratory information systems and revenue cycle management workflows.



©2026 CAP TODAY, all rights reserved.

---

## [The laboratory tests of pandemic summer](#)

written by CAP TODAY  
August 19, 2020

August 2020—In March, the COVID-19 pandemic came in like a lion—and has yet to leave, like a lamb or anything else. Instead, it roared through April and May in early hot spots like New York City and

New Orleans. As lockdowns took hold, the cautious hope was that by summer the virus would be tamed (if not simply go away “like a miracle” or “as the heat comes in,” per several infamous predictions), giving health care providers a chance to exhale before a likely second wave in the fall. Instead, June and July saw other cities and states hit hard in turn, while many places that appeared to have flattened the curve were starting to see concerning upticks in cases.



©2026 CAP TODAY, all rights reserved.

---

## [Targeting microbiology lab efficiency with AI](#)

written by CAP TODAY  
August 19, 2020

August 2020—Bringing an automated culture plate reading system into the Hennepin County Medical Center microbiology laboratory was never a question of if but when. “We need artificial intelligence to help us with active decision-making processes in the lab,” says Glen Hansen, PhD.



©2026 CAP TODAY, all rights reserved.

---

## [In 2020 checklist, a ‘gentle push’ to next quality level](#)

written by CAP TODAY  
August 19, 2020

August 2020—For quality management in the laboratory, it’s not enough to have checks and balances. The checks and balances have to work to improve quality. That’s how Stephen J. Sarewitz, MD, vice

chair of the CAP Checklists Committee, characterizes the changes to the quality management requirements in the 2020 laboratory general checklist, released in June.



©2026 CAP TODAY, all rights reserved.

---

## [Lab with Ebola experience: COVID more complicated](#)

written by CAP TODAY  
August 19, 2020

August 2020—If there's one thing scarier to experience than COVID-19, it's Ebola. Or so you might think. "Ebola was easier," says Beverly Dickson, MD, medical director of the clinical laboratory at Texas Health Presbyterian Hospital Dallas.



©2026 CAP TODAY, all rights reserved.

---

## [Steps to verifying SARS-CoV-2 antibody assays and what's known about protective immunity](#)

written by CAP TODAY  
August 19, 2020

August 2020—The CAP treats emergency use authorization assays similar to FDA-cleared assays and thus requires full verification. In a June 4 CAP webinar, Neil Anderson, MD, D(ABMM), assistant director of clinical microbiology, Washington University School of Medicine in St. Louis, walked through

how to approach verification for SARS-CoV-2 assays. Co-presenter Elitza Theel, PhD, D(ABMM), director of the infectious diseases serology laboratory at Mayo Clinic, reported what's known about protective immunity against SARS-CoV-2.



©2026 CAP TODAY, all rights reserved.

---

## [Tumor budding assessment in CRC: why and how](#)

written by CAP TODAY  
August 19, 2020

August 2020—Tumor budding is a robust prognostic marker that should be reported at least in pT1 and stage II colorectal carcinomas and taken into account with other risk factors. Further evidence is needed for tumor budding assessment in specimens taken after neoadjuvant therapy, says Heather Dawson, MD, senior staff GI pathologist at the Institute of Pathology, University of Bern in Switzerland.



©2026 CAP TODAY, all rights reserved.